Rosengart T K, Helm R E, DeBois W J, Garcia N, Krieger K H, Isom O W
Department of Cardiothoracic Surgery, New York Hospital-Cornell University Medical Center, NY, USA.
J Am Coll Surg. 1997 Jun;184(6):618-29.
Blood transfusion persists as an important risk of open heart operations despite the recent introduction of a variety of new pharmacologic agents and blood conservation techniques as independent therapies. A comprehensive multimodality blood conservation program was developed to minimize this risk.
To provide a strategy for operating without transfusion, this program was prospectively applied to 50 adult patients who are Jehovah's Witnesses and have undergone open heart operation at our institution since 1992. The blood conservation program used for these patients included the use of high-dose erythropoietin (800 U/kg load, 500 U/kg every other day), aprotinin (6 million U total dose full Hammersmith regimen), "maximal" volume intraoperative autologous blood donation, intraoperative cell salvage, continuous shed blood reinfusion, and drawing as few blood specimens as possible.
Procedures performed included first-time coronary bypass operations (n = 30) and more complex operations, including reoperations, valve replacements, and multiple valve replacements with or without coronary bypass (n = 20). Despite the absence of transfusion, the mean discharge hematocrit in these patients was greater than 30 percent, and there was no anemia-related mortality rate in this group. The overall in-hospital mortality for the group was 4 percent. A subset analysis was performed between the 30 first-time coronary bypass patients (group 1) and a control group of 30 consecutive patients who were not Jehovah's Witnesses but had undergone first-time coronary bypass during the same period (group 2). The blood conservation program described in the previous paragraph was not used in group 2 patients and specific transfusion criteria were prospectively applied. The chest tube output in group 1 patients was less than 40 percent of that for group 2 patients at all points measured after operation (p < 0.01). Postoperative hematocrit levels in group 1 were greater than those for group 2, despite the absence of red blood cell transfusion and despite a significantly lower admission hematocrit and red blood cell mass in group 1. The average length of stay and ancillary costs for the two groups were equivalent. Although group 1 and 2 patients were well matched for preoperative transfusion risk factors, none of the group 1 patients required transfusion, but 17 (57 percent) group 2 patients met transfusion criteria and received 3.0 +/- 4.8 U (mean plus or minus standard deviation) of homologous blood or blood products.
These results suggest that even complex open heart operations can be performed without homologous transfusion by optimally applying available blood conservation techniques. More generalized application of these measures may increasingly allow "bloodless" operations in all patients.
尽管最近引入了多种新的药物制剂和血液保护技术作为独立疗法,但输血仍然是心脏直视手术的一项重要风险。我们制定了一项全面的多模式血液保护计划,以尽量降低这一风险。
为了提供一种不输血进行手术的策略,自1992年以来,该计划前瞻性地应用于50例在我院接受心脏直视手术的耶和华见证会成年患者。用于这些患者的血液保护计划包括使用高剂量促红细胞生成素(负荷剂量800 U/kg,隔日500 U/kg)、抑肽酶(全量哈默史密斯方案总剂量600万U)、“最大量”术中自体血回输、术中血液回收、持续失血回输以及尽可能少采集血标本。
所施行的手术包括首次冠状动脉搭桥手术(n = 30)以及更复杂的手术,包括再次手术、瓣膜置换术以及伴有或不伴有冠状动脉搭桥的多次瓣膜置换术(n = 20)。尽管未输血,但这些患者出院时的平均血细胞比容大于30%,且该组无贫血相关死亡率。该组患者的总体住院死亡率为4%。对30例首次冠状动脉搭桥患者(第1组)和同期30例连续接受首次冠状动脉搭桥但并非耶和华见证会成员的对照组患者(第2组)进行了亚组分析。第2组患者未采用上一段所述的血液保护计划,而是前瞻性地应用了特定的输血标准。术后所有测量时间点,第1组患者的胸管引流量均不到第2组患者的40%(p < 0.01)。尽管第1组未输注红细胞,且入院时血细胞比容和红细胞量显著低于第2组,但第1组术后血细胞比容水平高于第2组。两组的平均住院时间和辅助费用相当。尽管第1组和第2组患者在术前输血风险因素方面匹配良好,但第1组患者均未输血,而第2组有17例(57%)患者符合输血标准并接受了3.0 +/- 4.8 U(均值加减标准差)的同种异体血液或血液制品。
这些结果表明,通过最佳应用现有的血液保护技术,即使是复杂的心脏直视手术也可以不进行同种异体输血。更广泛地应用这些措施可能会越来越多地使所有患者都能接受“无血”手术。